PhRMA head blasts Biden's war on cancer; AstraZeneca's underwhelming lung cancer drug trial

AstraZeneca's lung cancer drug outperformed standard-of-care chemotherapy in a trial, but investors were still disappointed.

July 7, 2023 Check out STAT+

Sponsored By

Elise Amendola/AP Opinion: Biden promised a 'war on cancer' — but declared war on the cure instead These policies "will harm our ability to develop new treatments for a whole host of diseases," writes PhRMA CEO and President Steve Ubl. By Stephen J. Ubl STAT+ | AstraZeneca shares fall after lung cancer drug underwhelms in trial The company reported positive results in an early look from an ongoing trial, but analysts had been expecting a clearer sign of benefit. By Andrew Joseph Drinking water from nearly half of U.S. faucets likely contains "forever chemicals": Study Drinking water from half of U.S. faucets likely contains per- and polyfluoroalkyl substances — potentially harmful "forever chemicals." By Associated Press Adobe Opinion: Sen. Bill Cassidy: Smart, practical ways to lower drug prices Congress can reduce drug prices without stifling innovation by tackling PBMs, 340B, "parking," the Orphan Drug Act, and more. By Bill Cassidy

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser